'Real-world' evidence for vedolizumab's clinical effectiveness and safety

Takeda Pharmaceutical (TYO: 4502) is presenting data on the real-world effectiveness and safety of vedolizumab in patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) during the United European Gastroenterology (UEG) Week in Vienna, Austria, October 16 to 19, 2016.

Findings indicated notable clinical remission rates, reductions in disease activity scores and improved mucosal healing in more than 5,000 patients with UC and CD receiving treatment with vedolizumab in real-world clinical practice, said Takeda, Japan’s largest drugmaker, whose drug was launched, under the trade name Entyvio, in 2014 for the treatment of adults with moderate to severe ulcerative colitis and Crohn's disease.